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1. Introduction 
There is a large and growing interest in the organization of the transfer of scientific 
knowledge created by universities to the private sector. Many highly innovative sectors such 
as robotics, electronics and the live sciences benefit from the results of university research. 
For example, Cockburn and Henderson (1998) calculate that research carried out in public 
institutions was used in 16 out of 21 medicines that, according to experts, have enjoyed the 
greatest therapeutic impact between 1965 and 1992.  
There are two main ways in which the knowledge created in universities has been 
transferred to firms. The prevailing way is through licensing agreements; the ground-
breaking way involves the creation of spin-offs. The empirical literature (Meyer, 2006) 
indicates that for a university, the option of creating a spin-off is, and indeed should be, the 
exception rather than the rule. University Technology Transfer Offices (TTOs), even 
successful ones, also express a clear preference for licensing contracts to channel the transfer 
of technology generated within universities. One important reason is that spin-off deals are 
much more complex to write and manage than licensing agreements. Often, a TTO starts a 
spin-off because an innovation is too embryonic to be easily developed and integrated inside 
a firm.  
In this paper, we describe the main steps in the transfer of university innovations, the main 
incentive issues that appear in this process, and the contractual solutions proposed to address 
them. In this manner, we also provide a short and necessarily biased review of papers that 
analyze contractual solutions to asymmetric information problems in licensing and venture 
capital contracts. Our main objective is to clearly state the main problems and solutions 
rather than to provide a comprehensive review of the literature. 
2. University licensing contracts  
University licensing contracts have many features in common with other licensing 
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agreements, with two important caveats. First, most university innovations require further 
development to be practically applicable, and thus, the involvement of the researcher (or the 
research team) responsible for the innovation is usually necessary for the success of early 
development phases. Second, a university never commercializes the final product; hence, it 
will not compete with a subsequent licensee in the product market. 
The two main elements of university licensing contracts are royalties and fixed fees. 
Royalties are payments that vary according to the quantity produced and sold using the new 
technology. They have the inconvenience of artificially increasing the licensee’s perceived 
marginal production cost. Therefore, the licensee will not increase its production as much as 
it otherwise would. Independent of the activities of the licensee once a new technology is 
incorporated, a fixed payment does not have this distorting effect, and outside of other 
considerations, it is in principle the optimal payment instrument to license a technology.  
A common argument in favor of payments that vary with the licensee’s output is that they 
allow risk sharing when revenues are uncertain, since it is difficult to anticipate the new 
production costs or product demand. If both the licensor and the licensee are risk-averse, 
then sharing revenues can be an efficient insurance mechanism; see the analysis of 
Bousquet, Cremer, Ivaldi and Wolkowiz (1998). In what follows, we shall ignore this risk-
sharing aspect to concentrate on the incentive characteristics of the contract terms.  
Figure 1 depicts the main decisions involved in a university-licensing contract; we 
distinguish between the development and commercialization stages. Note that R refers to the 
researcher, or the research team, and F refers to the firm. 
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Figure 1: Patent licensing with development and commercialization stages 
 
We begin by considering the moment at which the university (that is, the TTO and/or the 
researcher) and the firm design the contract. At this point, two possible informational 
problems can appear. First, the description of the innovation may not be rich enough to 
estimate its value, and thus the details of the discovery may not be publicly described. This 
may be because such a description would allow the innovation to be easily imitated, as 
happens once the logic behind a magic trick is revealed. Alternatively, there may be no 
patent that protects the technology that has been discovered. Obviously, a firm is willing to 
pay more for a more valuable innovation, and so the TTO has an interest in suggesting that it 
has a path-breaking discovery. If the university is better informed than the firm as to the 
value of the innovation, it can use royalties to signal the value of the innovation (Gallini and 
Wright, 1990, Macho-Stadler and Pérez-Castrillo, 1991). Indeed, under fixed payment, the 
TTO receives its money up front, independently of the firm’s revenues, while under a 
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variable payment, the amount depends upon firm production. Hence, royalties link the 
TTO’s profits to the value of the innovation, and thus, their inclusion signals a high-quality 
innovation. 
Second, it may also be the case that the firm is better informed than the TTO. Firms are in a 
much better position than the university to know market opportunities and the potential use 
of new technologies. In fact, universities are typically poorly informed about markets in 
general, and hence, they face an adverse selection problem. In this case, the licensee may 
claim that a patent has a low commercial value to obtain a low fee. The TTO thus must 
design a “menu” of contracts from which a firm chooses, thereby revealing its level of 
information. Macho-Stadler and Pérez-Castrillo (1991) show that a royalty should be 
included in the contract designed for an innovation with high commercial value, while a 
low-valued discovery should be licensed through a fixed fee. For a firm that places a high 
value on a patent, a royalty is costly, and so it would prefer a fixed payment contract. The 
contrary is true for a firm that places a low value on the patent; in this case, a royalty scheme 
is better since the firm will presumably produce and sell few units. 
Once a contract is signed, the development stage starts. The innovation is developed by the 
firm (and usually, inside the firm). However, the collaboration of the innovator is crucial to 
extract all the value of the innovation and thus adequately develop the new technology. 
Indeed, either the innovation that is provided by university licenses is at an embryonic stage 
(i.e., at a “proof of concept” stage), or only a laboratory prototype is available. Further 
development requires (or it is facilitated by) additional knowledge, an important part of 
which cannot be included in the patent description or the contract. The process of obtaining 
an innovation produces expertise or know-how, which may be vital for its development. The 
problems solved, the errors made, the strategies pursuit, and the intuitions built up during the 
innovation process are neither patentable nor publishable, but they are very useful to the 
development of the technology. However, it is difficult to commit to the transfer of this 
know-how. The inclusion of royalties in a contract provides incentives to this transfer, as the 
amount received by the university increases with the licensee’s revenues. We should then 
expect the presence of royalties to be positively correlated with the transfer of know-how 
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(Macho-Stadler, Martínez-Giralt and Pérez-Castrillo, 1996). Due to similar reasons, 
royalties also provide incentives to innovators to collaborate in the development of the 
innovation. Therefore, the more such collaboration is needed or the more embryonic the 
innovation is, the more likely we are to see royalties included in the licensing contract 
(Jensen and Thursby, 2001). 
Royalties are not the only way to structure a variable payment system. Holding shares or 
equity in the firm is an alternative way to make payments depend on the success of the new 
technology. The advantage of shareholding is that it does not distort firm costs and also 
works as a risk-sharing mechanism. However, in most cases, the licensed technology has a 
limited impact on overall firm profits; hence, most of the variation in these profits does not 
actually reflect the value of the new technology, which decreases the incentive properties of 
holding shares. Thus, shareholding is likely to appear only when the licensed technology is 
the core business of a small firm. Payments based on milestones, when they can be verified, 
may also be an attractive alternative to royalties, since they also do not distort output 
(Dechenaux, Thursby and Thursby, 2009b).   
In the development stage, one must also take into account the potential moral hazard 
concerning a firm’s allocation of funds and human resources during the development stage. 
Given that this stage is often carried out within a firm, it may be difficult for a third party to 
verify the firm’s decisions. If this contract is heavily based on royalties (or equity or 
milestones), then part of the earnings will go to the university, and the firm will have less 
interest in the success of this development stage. This leads to a trade-off, since the 
incentives that are needed to motivate the innovator and the firm move in opposite 
directions. An optimal licensing contract must balance the incentive effects of royalties or 
milestones for both the firm and the university researcher. 
Payments based on milestones, particularly technical milestones, may have additional 
advantages when the commercialization stage is taken into account. In this stage, the input 
from the researcher is usually not necessary (or is not crucial), while the main decisions 
come from the firm. Therefore, an optimal contract would require the university to not be 
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involved in payments starting at the commercialization stage. This can be achieved if all 
conditional payments to the university are made before this stage. Payments based on 
technical milestones (i.e., on the success of the development stage), when feasible, may be 
more efficient from an incentive point of view than payments based on commercial success 
like royalties or equity shares (Dechenaux, Thursby and Thursby, 2009a). 
Finally, early payments to the university and the inventor, including up-front fees, as well as 
annual fees that make it costly for a firm to keep a technology may be necessary to make 
sure that the licensee signs the contract with the intention to use the technology. This may 
prevent situations in which the firm wants to license an invention with the only objective of 
shelving it in case of success; for example, it may want to prevent competitors from 
accessing the technology (Dechenaux, Thursby and Thursby, 2009a).  
 
3. University spin-offs  
University spin-offs constitute the entrepreneurial route to commercializing public research. 
They are initiated either directly by the researcher (or laboratory) that made the discovery or 
by the university’s TTO. A spin-off agreement involves the TTO and the researcher as well 
as one outside financer, that is, either a venture capitalist (VC) or a business angel (BA). 
VCs are “formal” early-stage investors that create funds that pool and manage money. BAs 
are “informal” wealthy individuals that invest their own funds in a small set of new business 
ventures. Given that spin-offs take time to become profitable and lack tangible assets, debt 
financing by banks is typically not an option.  
Spin-off contracts are more complex than licensing agreements. They allocate both cash 
flow rights and control rights, the latter of which may or may not be associated with cash 
flow rights, to the main participants (i.e., the TTO, researcher and VC or BA) and possibly 
also to the manager who will be hired to run the venture. It is customary to distinguish two 
types of shares, namely, financial shares, which are directly related to the capital invested, 
and founder shares, which compensate for the intellectual property brought in by the 
researcher(s) and owned by the university’s TTO.  
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The very high level of scientific, financial and commercial uncertainty implies that each step 
in the venture may lead to the renegotiation of the previous contract and/or an increase in the 
financing of the spin-off; new financial shares may be issued, and new partners may be 
included. Also, a successful spin-off must decide its exit strategy either through acquisition 
by an existing company or through an Initial Public Offering (IPO). Given the different 
objectives that the participants in such contracts usually have, each renegotiation generates 
conflict, since decisions that benefit one participant do not necessarily benefit all.  
Figure 2 sketches the main elements in terms of decisions or information along the timeline 
of a typical spin-off. We have distinguished three stages, namely, the development stage, the 
commercial stage, and the exit stage. The major conflicts of interest happen between the 
financier(s) on one side and the researcher, and possibly the manager on the other side. The 
TTO is aligned with the financier with respect to some issues, but it is aligned with the 
researcher in other issues. To simplify, in the Figure 2 we denote the researcher together 
with the manager by R, even though the manager does not intervene in the initial contract. 
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 Figure 2: Spin-off with development, commercialization and exit stages 
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TTO financing is usually inefficient, given the difficulties TTOs usually encounter in raising 
funds, it is a good way to signal precisely because it is so costly. Hence, TTOs can own both 
founder and financial shares in some ventures.  
There are other ways to signal the profitability of a project. Many TTOs have no cash to 
invest; even if they do, they may prefer other ways to signal profitability or to complement 
or reinforce the signal sent through TTO financing with other signals. Kaplan and Strömberg 
(2003) argue that the ubiquitous presence of various types of convertible preferred stocks in 
the hands of VCs can be explained as a way to persuade VCs regarding the profitability of 
the project. Convertible preferred stocks are senior shares; hence, VCs typically receive 
everything in the case that the final value of the venture is not large. By maintaining junior 
claims, the researcher (and often the TTO) evidences confidence that the innovation is a real 
breakthrough with real chances to provide large profits. 
Finally, the inclusion in the contract of so-called “anti-dilution clauses” also helps to signal 
to financiers that no bad surprises are expected. These clauses allocate the incumbent 
investors additional shares during subsequent financing if the estimated value of the project 
is more negative and the price of the new issue is lower than their current values.  
Once a contract is signed and an investment is made according to contract (the investment is 
a verifiable variable), the major issue during the development stage is ensuring that the 
researcher and the entrepreneur engage in appropriate effort and decisions. At this stage, the 
non-financial contribution of the VC or BA does not seem as important as in the 
commercialization and exit stages; still, these partners may play a crucial role, for example, 
in the identification of a good management team. Researchers and managers obtain 
incentives through their participation in the company. A good part of their payment is in 
terms of shares, the number of which can increase as milestones are reached. It may also be 
the case that these actors take a (sometimes small) financial stake in the spin-off to reinforce 
their commitment. Moreover, in most cases the incentives of these participants are even 
stronger than suggested by their shares, as they hold claims that are junior to VC claims. 
Therefore, they have incentives to engage in ambitious projects. 
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The continuing presence of both the researcher and the manager is so crucial that most spin-
off contracts include clauses that make it costly for them to leave the venture (thus taking 
their human capital with them) once the project has started. Their shares are often vested 
over time so that a participant who leaves the spin-off receives only a part of his/her 
entitlement. Also, non-compete clauses prohibit them from working for a company with 
similar interests and in which their human capital may be more valuable for a certain period 
of time. 
There are other instruments that provide appropriate incentives for researchers and 
managers. First, financing during the development phase is often staged so that projects that 
are doomed to fail are not continued (Gompers, 1992). Staged financing also allows the 
financier to maintain some bargaining power at a stage in which the roles of researchers and 
entrepreneurs are so critical that these parties may try to renegotiate down an investor’s 
claim once an investment has been made (Neher, 1999). Second, anti-dilution clauses also 
provide incentives for completing the development phase with good prospects, as the 
relative shareholdings of researchers and entrepreneurs decrease given the increase in the 
number of shares of the current financier if the valuation of the venture is low. 
A crucial moment in the life of a spin-off is reached when the development stage has 
finished. If this milestone has been successfully accomplished, the next commercialization 
stage typically requires substantially more financing. The incumbent financier may not have 
the resources or the willingness to risk the large amount of investment necessary at this point 
in the venture. In any case, it is efficient in most situations that new financiers share risks 
with insiders. It is then necessary to value the firm so that a fair price in terms of shares is 
allocated to those bringing new money into the venture. However, insiders (i.e., researchers, 
managers, incumbent financiers and the TTO) have more accurate information than 
outsiders (i.e., new financiers) concerning firm assets; hence, a new asymmetric information 
problem emerges. This may not be the only relevant problem, as conflicts may arise among 
insiders. For example, the incumbent financier may have different objectives and tools than 
other participants. 
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As was the case when the spin-off was constituted, offering convertible preferred stocks to 
new financiers helps convince them of the profitability of the project; that is, offering senior 
claims signals projects with good prospects. The second signaling device is the further 
involvement of current participants, mainly the incumbent financier, in the venture. The 
situation here may be different depending on whether the first financier was a VC or a BA. 
Indeed, a VC has many more resources than a typical BA; hence, although it may not be 
efficient from a risk-sharing point of view, a VC has the possibility to cover a substantial 
fraction of the required additional financing. This constitutes one advantage of the 
involvement of a VC instead of a BA in the initial contract. However, this potential 
advantage can become a double-edged sword, as it provides the VC with strong bargaining 
power over the other participants that can be used to renegotiate the initial contract. The 
anticipation of this  “hold-up” problem may be very negative for the spin-off and, thus, also 
for the VC, since the incentives of researchers and managers to provide adequate time, 
effort, and resources in the development stage may be seriously compromised.  
Also, when the involvement of an incumbent financier in a new financing round is large, 
his/her interests may no longer be aligned with those of the rest of the participants. Indeed, 
while researchers, managers and the TTO are clearly interested in fixing a high price for the 
new stock (that is, offering few shares per Euro), the incumbent financier may prefer a low 
price if he/she will be covering a large part of the new financing, as this dilutes the stakes of 
the other participants. Fluck, Garrison and Myers (2006) argue that an ex-ante commitment 
to the syndication of later stages of financing may align a VC’s objectives with the interests 
of the other participants, since it precludes the incumbent VC from being a 
disproportionately large investor in subsequent financing rounds. Hence, syndication 
reduces the hold-up problem, which may explain why most later-stage VC investments are 
syndicated.  
The commercialization stage combines a need for further scientific and technical 
development of the product with a substantial advance in its commercialization. The 
involvement of the researcher is still important at this point, but input from the VCs (and 
BAs, if applicable) is also crucial, as they provide services such as the evaluation of business 
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opportunities, growth strategies, tracking and coaching of the company, identification of 
suppliers and other stakeholders and, later on, the preparation and execution of an exit 
strategy. Therefore, the moral hazard problem for VCs may be severe. 
In fact, the need for external advice may explain the financial involvement of VCs and/or 
BAs even in those few cases in which researchers and management (possibly together with 
the TTO) are able to fund the entire investment (Casamatta, 2003). The reason is that the 
financial participation of VCs and/or BAs provides them with incentives to supply services 
to the venture that would otherwise need to be provided by an external consultant requiring a 
high informational rent. Therefore, projects requiring a relatively small level of investment 
are optimally fully financed by VCs and/or BAs, while the financial involvement of 
researchers and management would be optimal if the required investment is large so that 
they also have the right incentives to engage in the project. Finally, an optimal contract must 
provide fair compensation to the financiers; hence, it allocates convertible bonds or 
preferred equity to them if the amount they invest is large; otherwise, manager and 
researcher are given preferred equity, and VCs and BAs receive common stocks. 
Stocks usually cannot provide the right incentives to all participants in a spin-off: to fully 
internalize the effects of his/her decisions, each participant would need to receive all shares. 
However, the convertible feature of securities that often appear in venture capital contracts 
has powerful incentive properties when the main decisions of the entrepreneur and/or 
researcher are made before those decisions made by financiers (Schmidt, 2003). In an 
optimally drafted contract, financiers will exert their conversion (i.e., debt-to-stock) rights if 
and only if they take adequate investment and service decisions. Given that these decisions 
are crucial to the success of the spin-off, entrepreneurs have incentives to take the actions 
that will push investors to convert and thus make the right decisions. 
If efforts by entrepreneurs and financiers are not sequential but simultaneous, the incentive 
properties of the convertible securities disappear. Then it is optimal to reward the VCs only 
when the profitability of the project has reached a certain level, which can achieved through 
warrants that yield positive payoff only if the firm value exceeds the strike price. See 
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Repullo and Suarez (2004), who assume that such efforts are complementary. However, this 
type of warrant does not seem to be common in venture capital contracts according to 
Kaplan and Strömberg (2003). 
The final stage of a successful spin-off is the exit, at which point the venture either is 
acquired or remains independent and moves through an IPO. All the main participants in the 
venture typically own a high number of shares of the company; hence, they have the 
common interest of maximizing its exit value. However, they also have conflicting 
objectives due to several reasons, which makes it difficult to design contracts that lead to an 
efficient exit decision. 
First, VC firms, especially young VC firms, have incentives to grandstand; that is, they take 
actions that signal their capacities to potential investors, in particular  by bringing companies 
public too early, which leads to underpricing, to raise their profiles and raise capital for new 
funds (Gompers, 1996). This conflict of interest among spin-off participants is also 
documented by Chahine, Filatotchev and Wright (2007), who show that VC behavior in 
IPOs is different from BA behavior. In their sample, initial underpricing is positively related 
to VC-retained ownership, but it is negatively related to BA-retained ownership. 
A second source of conflict is that while the main financial contributors (i.e., VCs, BA, and 
possibly the TTO) are only concerned about monetary returns, the manager (and possibly the 
researcher) cares about both pecuniary and non-pecuniary returns, such as reputation, 
specific human capital, maintenance of their position as manager of a publicly listed firm, 
and so on. A crucial instrument in reaching an efficient exit decision is the allocation of 
contingent control rights between management and financiers, depending on the profitability 
(or signals of profitability) of the project (Aghion and Bolton, 1992). In particular, the 
financiers should obtain decision rights when the expected profitability is low, while 
management should retain these rights otherwise. The empirical analysis of Kaplan and 
Strömberg (2003) provides support for this theory. 
The different participants in the venture can also face incentive problems if the exit occurs 
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under an IPO; that is, further development is necessary at this stage to bring the innovation 
to the market. Providing the right incentives requires an adequate allocation of shares, which 
may imply that the manager maintains a large number of shares. How is it then possible to 
reward the financiers when there is a large funding requirement? The answer is that they 
should obtain a more than fair compensation in case the optimal exit occurs through an 
acquisition (see Hellmann, 2006). The contract rewards the financiers through convertible 
preferred equity with automatic conversion at the IPO; therefore, reward to the financiers is 
proportionally larger in the case of acquisition. Moreover, to achieve an optimal choice 
among the exit options, the contract should provide control to the manager if there are good 
prospects for going public while control must be allocated to financiers if these prospects are 
not good. 
 
4. Some concluding thoughts  
In recent years, we have learned much about the consequences and possible remedies of the 
existence of ubiquitous asymmetric information at all steps of university technology 
transfers. In this paper, we have highlighted the major incentive problems and how contracts 
can deal with them. However, there are still many open questions, and thus, further research 
is necessary to better understand the optimal design of technology transfer agreements. We 
now comment on a subset of relevant issues. 
First, the role played by risk aversion in these contracts is not fully understood, particularly 
with respect to spin-off contracts. While there is a consensus that the risk involved in these 
agreements is very large and that even venture capitalists are risk-averse partners, all the 
models presented here (with the exception of Bousquet et al., 1998) assume that the 
participants are risk neutral and that some of them are subject to limited liability. This 
convenient hypothesis is very useful to analyze most incentive problems. However, risk 
aversion should also play a role in various aspects of contracts such as the type of financiers 
involved (i.e., VCs or BAs), the number of investors participating in the venture, the timing 
of funding, the eventual syndication of some of the stages of financing, and so on. 
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Second, some of the conflicts of interest that emerge among participants in spin-off deals 
require further investigation. The dynamic of these contracts implies that partners with 
objectives aligned today may become antagonists tomorrow. For example, the TTO may be 
close to the researcher when a contract is designed, but it may be closer to the VCs and BAs 
when the venture is about to reach an exit strategy. In addition, the harshness of the conflicts 
of interest may depend on the type of partner; a VC, for instance, may behave differently 
than a BA. The anticipation of these conflicts may have severe consequences on the 
incentives of participants in this venture. Although a few papers have analyzed some of 
these problems, further research should shed additional light on the optimal renegotiation 
protocols, allocation of control rights, and contract provisions. 
Third, many more empirical analyses and case studies are necessary. Very few authors have 
been able to study in detail licensing and venture capital contracts, and still fewer 
researchers have access to university contracts. Given their complexity, the meticulous 
analysis of the allocation of cash flow, voting and control rights, and the provisions and the 
renegotiations of these contracts would be extremely useful to understand the main problems 
that they address as well as to propose improvements in the contracts that could help solve 
these same problems in a more efficient way. 
Finally, asymmetric information and incentive issues are so prevalent in university 
technology transfers, particularly those involving the creation of spin-offs, that the design 
and management of these contracts thus become complex matters. The existence of a well-
organized TTO that can carry out these tasks adequately as well as the identification of 
promising innovations, management of intellectual property rights, and so on are crucial for 
a successful transfer. A good TTO provides services that, if supplied individually by each 
researcher, department or laboratory, would be quite expensive and/or difficult to finance. It 
may also allow the university to build up a reputation that it offers only promising 
innovations while shelving the others (Macho-Stadler, Pérez-Castrillo and Veugelers, 2007). 
There are a few analyses of TTO performance (Siegel, Wright, Chapple and Lockett, 2008), 
but very little is known about the organizational characteristics that help TTOs become 
successful and about the management of TTOs, although one exception with regard to the 
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latter is Debackere and Veugelers (2005). 
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